Q-omics provides the consensus-scored HTR5A profile across patient tissues and cancer cell-line models. HTR5A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HTR5A is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, HTR5A RNA expression shows 9,950 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where HTR5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR5A survival associations across molecular data types. HTR5A RNA expression shows survival associations in the most cancer types (14), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR5A RNA expression–survival associations across cancer types. High HTR5A expression shows unfavorable associations in LIHC, UVM, KICH, DLBC, SKCM and ACC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HTR5A RNA expression.
This table summarizes HTR5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HTR5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR5A shows lower tumor expression in COAD, READ, THCA, STAD and KIRC. The COAD box plot shows higher HTR5A RNA expression in normal versus tumor tissue (log2 FC = −0.007, t-test p = .009).
This table shows molecular features associated with HTR5A in patient tissues and cancer cell lines. In patient samples, HTR5A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
